Related Experiment Video
Updated: Aug 6, 2025

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Effect of Reduced Versus Usual Lipid Emulsion Dosing on Bilirubin Neurotoxicity and Neurodevelopmental Impairment in
Lindsay Holzapfel1, Cody Arnold2, Jon Tyson1
1The University of Texas Health Science Center at Houston.
Insights
Reduced lipid emulsion doses may decrease the risk of bilirubin neurotoxicity (BN) in premature infants. This study investigates the impact of lipid dosing and phototherapy on BN development and neurodevelopmental outcomes.
Area of Science:
- Neonatal Medicine
- Neuroscience
- Pharmacology
Background:
- Bilirubin neurotoxicity (BN) poses a significant risk for premature infants, leading to neurodevelopmental impairment.
- Standard lipid infusions may increase free fatty acids, displacing bilirubin from albumin and increasing unbound bilirubin (UB) passage into the brain.
- The risk of BN may be influenced by phototherapy methods (cycled vs. continuous).
Approach:
- A pilot factorial randomized controlled trial (RCT) involving infants born at ≤750 g or <27 weeks' gestational age.
- Infants were randomized to receive usual or reduced-dose lipid emulsion, stratified by phototherapy assignment.
- Measurements included daily free fatty acids and UB, brainstem auditory evoked responses (BAER) at 34-36 weeks, and neurodevelopmental assessments at 22-26 months.
Key Points:
- Investigates the interaction between lipid emulsion dosing and phototherapy in preventing BN.
- Utilizes a novel probe for daily measurement of free fatty acids and UB.
- Aims to address fundamental questions regarding lipid administration, free fatty acids, UB, and BN.
Conclusions:
- Findings could support the need for larger trials on reduced lipid dosing to mitigate BN risk.
- This study provides a unique opportunity to evaluate lipid dosing and phototherapy effects and their interaction.
- Addresses critical knowledge gaps in managing hyperbilirubinemia in extremely preterm infants.
Abstract:
: Bilirubin neurotoxicity ( BN ) occurs in premature infants at lower total serum bilirubin levels than term infants and causes neurodevelopmental impairment. Usual dose lipid infusions in preterm infants may increase free fatty acids sufficiently to cause bilirubin displacement from albumin, increasing passage of unbound bilirubin ( UB ) into the brain leading to BN and neurodevelopmental impairment not reliably identifiable in infancy. These risks may be influenced by whether cycled or continuous phototherapy is used to control bilirubin levels. : To assess differences in wave V latency measured by brainstem auditory evoked responses ( BAER ) at 34-36 weeks gestational age in infants born ≤750 g or <27 weeks' gestational age randomized to receive usual or reduced dose lipid emulsion (half of the usual dose) irrespective of whether cycled or continuous phototherapy is administered. : Pilot factorial randomized controlled trial ( RCT ) of lipid dosing (usual and reduced) with treatment groups balanced between cycled or continuous phototherapy assignment. Eligible infants are born at ≤750 g or <27 weeks' gestational age enrolled in the NICHD Neonatal Research Network RCT of cycled or continuous phototherapy. Infants will randomize 1:1 to reduced or usual dose lipid assignment during the first 2 weeks after birth and stratified by phototherapy assignment. Free fatty acids and UB will be measured daily using a novel probe. BAER testing will be performed at 34-36 weeks postmenstrual age or prior to discharge. Blinded neurodevelopmental assessments will be performed at 22-26 months. Intention-to-treat analyses will be performed with generalized linear mixed models with lipid dose and phototherapy assignments as random effects covariates, and assessment for interactions. Bayesian analyses will be performed as a secondary analysis. : Pragmatic trials are needed to evaluate whether lipid emulsion dosing modifies the effect of phototherapy on BN. This factorial design presents a unique opportunity to evaluate both therapies and their interaction. This study aims to address basic controversial questions about the relationships between lipid administration, free fatty acids, UB, and BN. Findings suggesting a reduced lipid dose can diminish the risk of BN would support the need for a large multicenter RCT of reduced versus usual lipid dosing. Trial Registration : Clinical Trials.gov, NCT04584983, Registered 14 October 2020, https://clinicaltrials.gov/ct2/show/NCT04584983 Protocol Version : Version 3.2 (10/5/2022).
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
09:36Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022